Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

Conditions

• Acute Myeloid Leukemia
• Acute Lymphoblastic Leukemia
• Myelodysplastic Syndrome

Interventions

• BIOLOGICAL: ATIR101
• PROCEDURE: Haploidentical hematopoietic stem cell transplantation (HSCT)
• PROCEDURE: TBI regime
• PROCEDURE: Non-TBI regime

Sponsor

Kiadis Pharma